09Feb 2023


Crossref Cited-by Linking logo
  • Abstract
  • Cite This Article as
  • Corresponding Author

Background: Gliomas are the most common primary malignant brain tumor and these are among the most challenging to treat successfully due to their property of invasion. Objective: We have accumulated substantial evidence indicating role of Cathepsin B (Cat B) in gliomas and correlated it with the proliferative marker Ki-67 to establish its role in progression of gliomas. Methods and Material: Histological sections of 140 primary brain tumors including 62 low grade glioma, 73 high grade glioma & five autopsy brain tissue were taken and processed according to the standard protocols. Grading was done after H & E staining according to World Health Organization (WHO) grade [1]. These cases were then stained immunohistochemically for Cat B and Ki-67. Cat B was scored from 0-6 based on the % of tumor cells stained and intensity of staining, in which 0 is no staining whereas 6 is highest staining score. Ki-67 was evaluated as the percentage of positively stained tumor cell nuclei out of the total tumor cells counted (n=1000). Results: All cases having Cat B score 5-6 were High grade while cases with Cat B score 0-4 were Low grade (p<0.001). The association between Cat B and Ki-67 was also found to be statistically significant. Mean survival of patients with Cat B score 0-4 was significantly higher as compared to patients with Cat B score 5-6 (p<0.001). Conclusions: Cat B immunostaining correlated with high histological score and was significantly associated with poor survival.

[Medha Misra, Ajay K. Singh, Preeti Agarwal, Mohit Mishra, Shivanjali Raghuvanshi, Madhumati Goel, Chhitij Srivastava (2023); CATHEPSIN B AS FUTURE PROGNOSTIC MARKER IN CASES OF GLIOMA Int. J. of Adv. Res. 11 (Feb). 44-52] (ISSN 2320-5407). www.journalijar.com

Dr. Medha Misr
Department of Pathology King George Medical University, Lucknow, India


Article DOI: 10.21474/IJAR01/16217      
DOI URL: http://dx.doi.org/10.21474/IJAR01/16217